Science Advances

Supplementary Materials for

Axonal transport of late endosomes and amphisomes is selectively modulated by local Ca²⁺ efflux and disrupted by PSEN1 loss of function

Pearl P. Y. Lie, Lang Yoo, Chris N. Goulbourne, Martin J. Berg, Philip Stavrides, Chunfeng Huo, Ju-Hyun Lee, Ralph A. Nixon*

*Corresponding author. Email: nixon@nki.rfmh.org

Published 29 April 2022, *Sci. Adv.* **8**, eabj5716 (2022) DOI: 10.1126/sciadv.abj5716

The PDF file includes:

Figs. S1 to S7 Table S1 Legend for data S1

Other Supplementary Material for this manuscript includes the following:

Data S1





4.0 Ctrl ML-SA1 PSEN1 KO

PSEN1 KO Ctrl





Fig. S1. Lysosomal deficits and calcium dysregulation in *PSEN1* KO neurons (related to Fig. 1).

(A-B) Fractionation of the post-nuclear supernatant (PNS) resulted in the "LE-Lyso" fraction (mixture of LEs, amphisomes and lysosomes) and the "Flow" fraction (flow through; other organelles and cytosol). (A) Representative immunoblots of various organelle markers. 8 µg protein per lane. LIMP2 blot has been shown in Figure 4. (B) Relative protein levels in the LE-Lyso fraction of *PSEN1* KO. Ctrl level in each experiment is set as 100% (red line). n = 3-4experiments. (C-D) Active CTSD was labeled with Bodipy-pepstatin A in live neurons. (C), representative images of perinuclear areas. (D), quantification of average signal intensities. n = 43 Ctrl, 52 PSEN1 KO neurons. (E) Acidic organelles were labeled with LysoTracker (LT)-Red. Average signal intensities in the perinuclear area were quantified. n = 22 Ctrl, 20 PSEN1 KO neurons. (F) Lysosomal pH measurement in Ctrl, ML-SA1-treated Ctrl and PSEN1 KO neurons. Bars = mean + SEM (n = 27, 31 and 30 wells, respectively, for Ctrl, ML-SA1-treated Ctrl and *PSEN1* KO). *p < 0.05, ** p < 0.01, Kruskal Wallis test with Dunn's multiple comparisons against Ctrl. (G) LC3-RFP-GFP was expressed in Ctrl and PSEN1 KO neurons. Percentages of acidic LC3 vesicles (red only) in proximal-mid axons were quantified. n = 12 Ctrl, 11 *PSEN1* KO axons. (H) Cytosolic calcium was labeled with Oregon green 488-Bapta AM in live neurons grown in microfluidics devices. Average signal intensities were quantified within microgrooves. n = 51 Ctrl, 50 *PSEN1* KO axons. (**B**, **D**, **E**, **G**, **H**) Bars = mean + SEM. *p < 0.05, ** p < 0.01, Student's t-test against Ctrl. A.U., arbitrary unit. (I) Representative immunoblots of select gamma secretase components in PNS of Ctrl and PSEN1 KO neurons. NCT, nicastrin. No significant changes were detected.



Β



Fig. S2. Retrograde transport of axonal Rab7+ LT+ vesicles is impaired in *PSEN1* KO neurons (related to Fig. 1).

Time-lapse imaging in axonal segments of Ctrl and *PSEN1* KO neurons expressing Rab7-GFP and co-labeled with LysoTracker (LT)-Red. (A) Representative kymographs. Scale bar = 5 μ m. (B) Quantitative analyses of (A). Overall motility is represented by % retrograde (retro), non-motile (<0.1 μ m/s) and anterograde (antero) vesicles in Rab7+ LT+ vesicle subpopulation. Bars = mean + SEM (n = 10 Ctrl neurons and 10 *PSEN1* KO neurons). ** p < 0.01, Student's t-test.



Ε



F





Fig. S3. Axonal transport of mitochondria is not impaired in *PSEN1* KO or ML-SA1treated Ctrl neurons and mitochondrial Ca²⁺ level is not affected by *PSEN1* KO and Ned-19 treatment (related to Fig. 1).

(A-D) Time-lapse imaging in axonal segments in Ctrl, *PSEN1* KO and ML-SA1-treated Ctrl neurons expressing DsRed2-Mito. (A, C) Representative kymographs. Scale bar = 5 μ m. (B, D) Overall motility represented by the % retrograde (retro), non-motile (<0.1 μ m/s) and anterograde (antero) mitochondria. Bars = mean + SEM. N = 22 Ctrl, 22 *PSEN1* KO neurons in (B); n = 25 Ctrl, 24 ML-SA1-treated Ctrl neurons in (D). (E-F) Quantitative analysis of mitochondrial Ca²⁺ level. Mitochondria were labeled with MitoTracker-green and mitochondrial Ca²⁺ was co-labeled with Rhod-2 AM. To prevent Rhod-2 AM accumulation in endosomes and lysosomes, labeling and imaging were performed at room temperature. Only MitoTracker+ vesicles were analyzed. (E) Representative images. Scale bar = 5 μ m. (F) Graph showing the percentage of MitoTracker vesicles with detectable Rhod-2 AM signal. NoTx, untreated.

Α



В

Analysis of the most acidic 10% of vesicles



Fig. S4. Analysis of vesicle motility vs. acidification (related to Fig. 1).

Time-lapse imaging in axonal segments of LAMP1-mCherry-expressing Ctrl neurons loaded with equal amounts of dextrans conjugated with Alexa Fluor-647 (AF647) and Oregon green-488 (OG488) (see Figure 1E, F). (**A**) LAMP1+ AF647+ OG488+/– vesicles were sorted into 10 groups based on their acidification (reflected by OG488:AF647 ratio; low ratio indicates low pH). Box-and-whisker plots show the average velocity of vesicles in each group with individual datapoints represented by dots (whiskers = minimum and maximum datapoints). Group #1 (i.e. the most acidic 10% of vesicles) was determined to be exclusively retrograde (retro), with significant difference from the Groups #7, #8 and #10 that show substantial anterograde motility (antero) vesicles. *p < 0.05, **P < 0.01, Kruskal-Wallis test followed by Dunn's multiple comparisons (n = 36-37 vesicles per group). The most acidic 10% of vesicles were thus defined as the population of interest (i.e. acidic LEs/amphisomes with exclusive retrograde motility) in our analyses of Ctrl vs *PSEN1* KO (Figure 1E, F). (**B**) Same graph as in the bottom graph of Figure 1F supplemented with individual data points.



Fig. S5. Peptide competition assay to confirm specificity of p-DIC antibody (related to Fig. 4, 5, 6, 8).

A peptide competition assay was performed to verify that this antibody specifically recognizes p-DIC S80, but not the non-phosphorylated epitope. Equal amounts of neuronal lysate were immunoblotted with the p-DIC antibody only (left lane), or in the presence of 400-fold molar excess of peptides containing either phosphorylated (middle lane) or non-phosphorylated DIC S80 (right lane). These blots were processed and exposed simultaneously. The p-DIC-S80containing peptide completely abolished the signal, but the non-phosphorylated peptide had no effect, thus clearly illustrating the specificity of this antibody against the phosphorylated epitope.



С





D

Fig. S6. Retrograde transport of axonal LAMP+ LT+ vesicles is impaired by DIC1B-S80D overexpression, causing neuritic dystrophy (related to Fig. 5).

(A-B) Time-lapse imaging in axonal segments of Ctrl neurons expressing LAMP1-YFP and colabeled with LysoTracker (LT)-Red, co-expressing either flag-tagged wild-type DIC1B or flagtagged DIC1B-S80D. (A) Representative kymographs. Scale bar = 5 μ m. (B) Quantitative analyses of (A). Overall motility is represented by % retrograde (retro), non-motile (<0.1 μ m/s) and anterograde (antero) vesicles in each LAMP1 vesicle subpopulation. Bars = mean + SEM (n = 10 neurons in each group). ** p < 0.01, Student's *t*-test. (C-D) Quantitative analysis of dystrophic neurites in Ctrl neurons expressing either mCherry-tagged wild-type DIC1B (red) or mCherry-tagged DIC1B-S80D (red), and co-expressing LAMP1-YFP (green). Dystrophic swellings were identified by an apparent thickness of a least 1.3 μ m and positivity in both LAMP1-YFP and APP (immunostained, shown in gray scale). (C) Scale bar = 5 μ m. (D) Graph showing the number of swellings identified per neuron, Bar = mean + SEM (n = 79 neurons in DICwt group and 77 neurons in S80D group). **p < 0.01, Student's t test.



Fig. S7. Retrograde transport of axonal LAMP+ LT+ vesicles is not affected in embryonic *PSEN1* KI neurons (related to Fig. 8).

Time-lapse imaging in axonal segments of WT and *PSEN1* KI neurons expressing LAMP1-YFP and co-labeled with LysoTracker (LT)-Red. (A) Representative kymographs. Scale bar = 5 μ m. (B) Quantitative analyses of (A). Overall motility is represented by % retrograde (retro), non-motile (<0.1 μ m/s) and anterograde (antero) vesicles in LAMP1+ LT+ vesicle subpopulation. Bars = mean + SEM (n = 10 neurons in each group).

Table ST. Antibules used in this study	Table	S1. A	ntibo	odies	used	in	this	study	·.
--	-------	-------	-------	-------	------	----	------	-------	----

1 able S1. Antibodies used in this study.						
Antibodies against dynein- & kinesin-related proteins	Source (Catalog no.)					
DHC (Dynein heavy chain)	Santa Cruz (sc-9115)					
DIC1/2 (Dynein intermediate chain 1/2)	Millipore (MAB1618)					
DIC1 (Dynein intermediate chain 1)	GeneTex (GTX112418)					
p-DIC (phospho-dynein intermediate chain)	Biomatik (custom made)					
LIC1 (Dynein light intermediate chain 1)	GeneTex (GTX120114)					
DYNLL1 (Dynein light chain LC8-type 1)	BD Biosciences (610726)					
DYNLT1 (Dynein light chain Tctex-type 1)	Proteintech (11954-1-AP)					
DYNLRB2 (Dynein light chain Roadblock-type 2)	Abcam (ab107721)					
p150 (Dynactin subunit 1)	Abcam (ab11806)					
p50 (Dynactin subunit 2)	Millipore (AB5869)					
Arp1 (Actin-related protein 1)	Millipore (AB6058)					
Snapin (SNAP-associated protein)	Proteintech (10055-1-AP)					
LIS1 (Lissencephaly 1)	Abcam (ab2607)					
Nudel (NudE-like)	Abcam (ab25959)					
KIF3A (Kinesin family member 3A)	Covance (MMS-198P)					
KIF5A (Kinesin family member 5A)	Santa Cruz (sc-13353)					
KIF5C (Kinesin family member 5C)	GeneTex (GTX45387)					
KLC1 (Kinesin light chain 1)	Santa Cruz (sc-13362)					
Antibodies against MAPKs	Source (Catalog no.)					
JNK (c-Jun N-terminal kinase)	Cell Signaling (9252)					
p-JNK (phospho-JNK Thr183/Tyr185)	Cell Signaling (9255)					
ERK (extracellular signal-regulated kinase 1/2)	Cell Signaling (9107)					
p-ERK (phospho-ERK 1/2 Thr202/Tyr204)	Cell Signaling (9101)					
Antibodies against organelle markers/ loading controls	Source (Catalog no.)					
LIMP2 (Lysosomal integral membrane protein type-2)	Novus Biologicals (NB400-129)					
LAMP1 (Lysosomal associated membrane protein 1)	Developmental Studies Hybridoma Bank (1D4B)					
LAMP2 (Lysosomal associated membrane protein 2)	Developmental Studies Hybridoma Bank (ABL-93)					
Rab7 (Ras-related protein Rab7)	Abcam (ab50533)					
CatD (Cathepsin D)	Generated in house					
MPR (cation-independent mannose-6-phosphate receptor)	Sigma (HPA011332)					
LC3 (Microtubule-associated protein 1 light chain 3)	Novus Biologicals (NB100-2220)					
EEA1 (Early endosome antigen 1)	Santa Cruz (sc-33585)					
Calnexin	Enzo (ADI-SPA-860)					
TOM20 (Translocase of outer membrane 20)	Santa Cruz (sc-11415)					
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)	Santa Cruz (sc-25778)					
β-actin	Novus Biologicals (NB110-67828)					
APP	gift from Dr. Paul Mathews (C1/6.1)					
Secondary antibodies for immunocytochemistry	Source (Catalog no.)					
Alexa Fluor 488 AffiniPure goat anti-rat IgG	Jackson ImmunoResearch (112-545-167)					
Alexa Fluor 568 goat anti-rabbit IgG, highly cross adsorbed	Thermo Fisher (A11036)					
Alexa Fluor 633 AffiniPure goat anti-mouse IgG2b	Jackson ImmunoResearch (115-605-207)					

Data S1. (separate file)

Excel file containing source data for all figures, tables, and supplementary figures.